Q4 FY26 results: PAT ₹1,026M, new Board Chairman appointed

Revenue DeclineExceptional ItemResults View source PDF

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.6%1-day move

₹3460.10

prior close

₹3468.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.2+0.3+0.4-0.1-1.6-1.7-1.6-1.8-2.0-5.4-7.8-11.1-3.0—

Up moveDown movePending

AI summary

Sanofi India reported Q4 FY26 revenue of ₹4,723M, down ~12% YoY from ₹5,359M, though up ~12% QoQ. PAT stood at ₹1,026M vs ₹1,195M YoY, with EPS of ₹44.55. The insulin portfolio delivered double-digit growth for a second straight quarter, but overall results were hit by partnership transition transactions. FY25 (ended Dec 31, 2025) had exceptional items of ₹273M for personnel separation costs. Two Independent Directors (Mr. Aditya Narayan, Mrs. Usha Thorat) completed their tenure; Mr. Rahul Bhatnagar appointed as new Board Chairman. Auditors issued an unqualified limited review report.

Likely market impact

Revenue declined YoY but PAT and margins improved sequentially. Insulin strength is positive; leadership transition noted. Clean auditor review.